SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

ReShape Lifesciences Inc. RSLS NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

ReShape Lifesciences Inc. (RSLS) is a Medical - Devices company in the Healthcare sector, currently trading at $3.92. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $319,714, -42.2%/yr average growth. Net income is $10M (loss), growing at +21.9%/yr. Net profit margin is -3277.2% (negative). Gross margin is 68.4% (+7.9 pp trend).

Balance sheet: total debt is $31,258 against $4M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 1.99 (strong liquidity). Debt-to-assets is 0.5%. Total assets: $6M.

Analyst outlook: 1 / 3 analysts rate RSLS as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

RSLS SharesGrow Score Overview

41/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RSLS

No analyst coverage available for this stock.

RSLS: -42.2%/yr revenue is, +21.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet RSLS: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 1.99 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

RSLS: Gross margin is 68.4% (+7.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 3 analysts rate RSLS as buy (33%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

RSLS: Net profit margin is -3277.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range2.8-1212.99

Volume13.59M

Avg Volume (30D)943.7K

Market Cap$2.34M

Beta (1Y)1.90

Share Statistics

IPO Date2016-10-06

Employees17

CEOPaul F. Hickey

Financial Highlights & Ratios

Revenue (TTM)$319.71K

Gross Profit$218.77K

EBITDA$-10.34M

Net Income$-10.48M

Operating Income$-10.35M

Total Cash$4.98M

Total Debt$31.26K

Net Debt$-4.95M

Total Assets$6.5M

Price / Sales (P/S)7.31

Analyst Forecast

Rating ConsensusHold

Analysts Covering3

Buy 33% Hold 67% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS92943X1046

Price Chart

RSLS

ReShape Lifesciences Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Devices

2.80 52WK RANGE 1,212.99

People Also View

Helius Medical Technologies, Inc.

Inspira Technologies Oxy B.H.N. Ltd.

NeuroMetrix, Inc.

Sintx Technologies, Inc.

Tenon Medical, Inc.

Talis Biomedical Corporation

Heart Test Laboratories, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message